| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
1 Dana Farber Cancer Institute, Brigham and Women’s Hospital and Massachusetts General Hospital, Boston, Massachusetts;
2 Universitaets-Klinikum, Mainz, Germany;
3 Glasgow Royal Infirmary, Glasgow, United Kingdom;
4 Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia;
5 Novartis Oncology, East Hanover, New Jersey and Basel, Switzerland; and
6 Institut Gustave Roussy, Villejuif, France
Purpose: The purpose of our study was to assess the objective response to imatinib administered to patients with small cell lung cancer (SCLC).
Experimental Design: Eligible patients were those with SCLC who either had chemotherapy-naive extensive-stage or had SCLC in a sensitive relapse. Patients enrolled on the trial were treated with 600 mg of imatinib daily. The response was assessed using Southwest Oncology Group (SWOG) criteria after 3 and 6 weeks. Tumor specimens were examined by immunohistochemistry for the KIT receptor.
Results: Nineteen patients with SCLC entered on the study, including 16 men and 3 women. Nine patients had previously untreated extensive-stage disease and 10 patients had sensitive relapse. A central pathology review confirmed SCLC in only 14 of the 19 patients. There were no objective responses; however, one patient with sensitive-relapse disease had prolonged stabilization of disease (>3 months) while on imatinib therapy. The median time to progression was 0.8 months (range, 0.6–1.3 months) and 1.2 months (range, 0.2–4.1 months) in the previously untreated and sensitive-relapse groups, respectively. Tumor tissue samples from 4 (21%) of the 19 patients had the KIT receptor (CD117).
Conclusions: There was no observed antitumor activity in this limited Phase II trial of patients with SCLC, of which only a few tumors showed expression of the imatinib target. The results of this trial are, thus, inconclusive about the antitumor activity of imatinib against SCLC with the targeted KIT receptor (CD117). Further testing of imatinib in patients with SCLC will focus on demonstration of KIT expression in the setting of confirmed SCLC histology.
Commentary
Clin. Cancer Res. 2003 9: 5825-5828.
This article has been cited by other articles:
|
|
 |
|
  R. H. El-Maraghi and E. A. Eisenhauer Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III J. Clin. Oncol., March 10, 2008; 26(8): 1346 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ali, Y. Lin, M. M. Gharibo, M. K. Gounder, M. N. Stein, T. F. Lagattuta, M. J. Egorin, E. H. Rubin, and E. A. Poplin Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors Clin. Cancer Res., October 1, 2007; 13(19): 5876 - 5882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Hanrahan and J. V. Heymach Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4617s - 4622s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Steeghs, J. W. R. Nortier, and H. Gelderblom Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments Ann. Surg. Oncol., February 1, 2007; 14(2): 942 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Baranowska-Kortylewicz, M. Abe, J. Nearman, and C. A. Enke Emerging Role of Platelet-Derived Growth Factor Receptor-{beta} Inhibition in Radioimmunotherapy of Experimental Pancreatic Cancer Clin. Cancer Res., January 1, 2007; 13(1): 299 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ishikubo, K. Akagi, M. Kurosumi, K. Yamaguchi, T. Fujimoto, H. Sakamoto, Y. Tanaka, and A. Ochiai Immunohistochemical and Mutational Analysis of c-kit in Gastrointestinal Neuroendocrine Cell Carcinoma Jpn. J. Clin. Oncol., August 1, 2006; 36(8): 494 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, et al. Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR{alpha}, PDGFR{beta}, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung J. Clin. Oncol., December 1, 2005; 23(34): 8774 - 8785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Dy, A. A. Miller, S. J. Mandrekar, M.-C. Aubry, R. M. Langdon Jr., R. F. Morton, S. E. Schild, J. R. Jett, and A. A. Adjei A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study Ann. Onc., November 1, 2005; 16(11): 1811 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tsurutani, K. A. West, J. Sayyah, J. J. Gills, and P. A. Dennis Inhibition of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway but not the MEK/ERK Pathway Attenuates Laminin-Mediated Small Cell Lung Cancer Cellular Survival and Resistance to Imatinib Mesylate or Chemotherapy Cancer Res., September 15, 2005; 65(18): 8423 - 8432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Krause and R. A. Van Etten Tyrosine Kinases as Targets for Cancer Therapy N. Engl. J. Med., July 14, 2005; 353(2): 172 - 187. [Full Text] [PDF]
|
|
|
|
|
|
G. S. Warshamana-Greene, J. Litz, E. Buchdunger, C. Garcia-Echeverria, F. Hofmann, and G. W. Krystal The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy Clin. Cancer Res., February 15, 2005; 11(4): 1563 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tamborini, L. Bonadiman, T. Negri, A. Greco, S. Staurengo, P. Bidoli, U. Pastorino, M. A. Pierotti, and S. Pilotti Detection of Overexpressed and Phosphorylated Wild-Type Kit Receptor in Surgical Specimens of Small Cell Lung Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8214 - 8219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gambacorti-Passerini, R. Piazza, L. Tornaghi, S. Pilotti, and E. Pogliani Development of c-Kit-expressing Small-Cell Lung Cancer in a Chronic Myeloid Leukemia Patient During Imatinib Treatment J Natl Cancer Inst, November 17, 2004; 96(22): 1723 - 1724. [Full Text] [PDF]
|
|
|
|
|
|
P. Th. Went, S. Dirnhofer, M. Bundi, M. Mirlacher, P. Schraml, S. Mangialaio, S. Dimitrijevic, J. Kononen, A. Lugli, R. Simon, et al. Prevalence of KIT Expression in Human Tumors J. Clin. Oncol., November 15, 2004; 22(22): 4514 - 4522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Heymach, D. H. Johnson, F. R. Khuri, H. Safran, L. L. Schlabach, F. Yunus, R. F. DeVore III, P. M. De Porre, H. M. Richards, X. Jia, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer Ann. Onc., August 1, 2004; 15(8): 1187 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Johnson Imatinib for Small Cell Lung Cancer, Aiming for a Target in Vivo Clin. Cancer Res., May 15, 2004; 10(10): 3235 - 3236. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Heinrich Is KIT an Important Therapeutic Target in Small Cell Lung Cancer?: Commentary re: B. E. Johnson et al., Phase II Study of Imatinib in Patients with Small Cell Lung Cancer. Clin. Cancer Res., 9: 5880-5887, 2003. Clin. Cancer Res., December 1, 2003; 9(16): 5825 - 5828. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
